alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 501–525 of 1,139 studies published 2023 (page 21 of 46) · 27,780 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 13,259 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

The prevalence and risk factors study of cognitive impairment: Analysis of the elderly population of Han nationality in Hunan province, China

✓ Peer-reviewed alzhub usefulness score 51 out of 100. CNS Neuroscience & Therapeutics 2023-09-22

The prevalence of cognitive impairment, MCI, and dementia among participants aged 60 years and older were 21.48% (95% CI, 19.90-23.10), 15.70% (95% CI, 14.30-17.10), and 5.77 (95% CI, 4.90-6.70), respectively. 5 key findings →

Design: cross-sectional Participants: 3,233 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Medicare Advantage Enrollment and Disenrollment Among Persons With Alzheimer Disease and Related Dementias

✓ Peer-reviewed alzhub usefulness score 51 out of 100. JAMA Health Forum 2023-09-15

In this cross-sectional study of the Medicare population with acute and postacute care use, beneficiaries with ADRD had increasing enrollment in the Medicare Advantage program, proportional to the growth in overall enrollment, but their disenrollment from Medicare Advantage in the following year remained higher compared with beneficiaries without ADRD. 4 key findings →

Design: cross-sectional Participants: 18 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Lecanemab: Appropriate Use Recommendations

✓ Peer-reviewed alzhub usefulness score 51 out of 100. The Journal of Prevention of Alzheimer s Disease 2023-03-22

Lecanemab (Leqembi®) is approved in the United States for the treatment of Alzheimer's disease (AD) to be initiated in early AD (mild cognitive impairment [MCI] due to AD or mild AD dementia) with confirmed brain amyloid pathology.

Full summary, score breakdown and related studies → Original source Free full text

Blood Neurofilament Levels Predict Cognitive Decline across the Alzheimer's Disease Continuum

✓ Peer-reviewed alzhub usefulness score 51 out of 100. International journal of molecular sciences 2023-12-11

Neurofilament light chain (NfL) is a potential diagnostic and prognostic plasma biomarker for numerous neurological diseases including Alzheimer's disease (AD). 1 key finding →

Participants: 350 Evidence: low

Full summary, score breakdown and related studies → Original source

Proteomic clusters underlie heterogeneity in preclinical Alzheimer's disease progression

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Brain : a journal of neurology 2023-07-01

Heterogeneity in progression to Alzheimer's disease (AD) poses challenges for both clinical prognosis and clinical trial implementation. 3 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

The effects of low-dose radiation therapy in patients with mild-to-moderate Alzheimer's dementia: an interim analysis of a pilot study

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Radiation oncology journal 2023-06-26

One of the five patients with AD treated with LDRT experienced a temporary improvement in SNSB-II. 1 key finding →

Design: randomized controlled trial Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Reminiscence and Digital Storytelling to Improve the Social and Emotional Well-Being of Older Adults With Alzheimer's Disease and Related Dementias: Protocol for a Mixed Methods Study Design and a Randomized Controlled Trial

✓ Peer-reviewed alzhub usefulness score 50 out of 100. JMIR research protocols 2023-09-07

Studies suggest that reminiscence strategies combined with an intergenerational approach may yield significant social and mental health benefits for participants. 4 key findings →

Design: randomized controlled trial Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

TREM2+ macrophages suppress CD8+ T-cell infiltration after transarterial chemoembolisation in hepatocellular carcinoma

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Journal of hepatology 2023-03-06

& aims The immune landscape of hepatocellular carcinoma (HCC) following transarterial chemoembolisation (TACE) remains to be clarified. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Spatial and Temporal Mapping of Breast Cancer Lung Metastases Identify TREM2 Macrophages as Regulators of the Metastatic Boundary

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Cancer discovery 2023-12-01

Cancer mortality primarily stems from metastatic recurrence, emphasizing the urgent need for developing effective metastasis-targeted immunotherapies. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

TREM2 Deficiency Aggravates NLRP3 Inflammasome Activation and Pyroptosis in MPTP-Induced Parkinson's Disease Mice and LPS-Induced BV2 Cells

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Molecular neurobiology 2023-11-02

Microglia-mediated neuroinflammation plays a crucial role in the pathogenesis of Parkinson's disease (PD). 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Osteopontin characterizes bile duct-associated macrophages and correlates with liver fibrosis severity in primary sclerosing cholangitis

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Hepatology (Baltimore, Md.) 2023-08-02

Primary sclerosing cholangitis (PSC) is an immune-mediated cholestatic liver disease for which pharmacological treatment options are currently unavailable. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Trends in Incident Dementia Diagnosis Before and After Medicare Risk Adjustment

✓ Peer-reviewed alzhub usefulness score 50 out of 100. JAMA Network Open 2023-12-15

This cohort study examines rates of new diagnosis of Alzheimer disease and related dementias among beneficiaries of Medicare Advantage plans vs traditional Medicare from 2016 through 2020. 1 key finding →

Design: cohort study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Disparate Dementia Risk Factors Are Associated with Cognitive Impairment and Rates of Decline in African Americans

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Annals of Neurology 2023-12-09

Hypertension, hypercholesterolemia, obesity, and diabetes were overrepresented in AA participants, but were not associated with cognitive impairment. 5 key findings →

Participants: 261 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Neurovascular glial unit: A target of phytotherapy for cognitive impairments

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Phytomedicine : international journal of phytotherapy and phytopharmacology 2023-08-02

Herbal medicines demonstrate great potential to prevent cognitive impairment. 1 key finding →

Design: systematic review Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Stem cell-conditioned medium is a promising treatment for Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Behavioural brain research 2023-06-11

The obtained data revealed that MSC-CMs might positively affect neurodegenerative diseases prognosis, especially AD, through various mechanisms, including a decrease in neuro-inflammation, reduction of oxidative stress and Aβ formation, modulation of Microglia function and count, reduction of apoptosis, induction of synaptogenesis and neurogenesis. 3 key findings →

Design: systematic review Evidence: high

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Pathogenomic Signature and Aberrant Neurogenic Events in Experimental Cerebral Ischemic Stroke: A Neurotranscriptomic-Based Implication for Dementia

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Journal of Alzheimer's disease : JAD 2023-01-01

This study has established a panel of highly important DEGs to signify the potential therapeutic targets for neuroregenerative strategy against pathogenic events associated with cerebral stroke. 4 key findings →

Design: meta-analysis Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

AD-BERT: Using pre-trained language model to predict the progression from mild cognitive impairment to Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Journal of biomedical informatics 2023-07-08

The use of EHRs for AD-related research is promising, and AD-BERT shows superior predictive performance in modeling MCI-to-AD progression prediction. 1 key finding →

Participants: 3,657 Evidence: low

Full summary, score breakdown and related studies → Original source

Serum biomarkers associated with aging and neurodegeneration in common marmosets (Callithrix jacchus)

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Neuroscience letters 2023-11-23

The common marmoset (Callithrix jacchus), a small South American monkey, is an important nonhuman primate model in the study of aging and age-related neurodegenerative disease, including Alzheimer's disease, Parkinson's disease, and related dementias. 1 key finding →

Participants: 13 Evidence: low

Full summary, score breakdown and related studies → Original source

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed